Powered by
HISTALIM is The First European Laboratory to Adopt the Vectra® Polaris(TM) Automated Quantitative Pathology Imaging System Developed by PerkinElmer, Inc. Which Enables Scientists to Analyze up to 7 Markers on 1 Single Slide

In 2016 HISTALIM observed an increasing demand from its customers and partners for multiplex imagery. The company leads several development programs and is involved in numerous clinical trials in the field of cancer immuno therapies. In this particular area HISTALIM performs studies which aim at characterizing the tumor microenvironment and its interaction with immune cells.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170

Sign up for unrestricted access to 200+ subscription services.
Already have an account? Click here to login.

RelSci News & Alerts gets you:

  • 5 free articles a month from top subscription outlets like the Financial Times, New York Times, and Washington Post
  • Competitive business intelligence through daily data updates
  • Custom feeds on target high-value individuals, companies, industries, and topics delivered straight to your inbox